IPN Ipsen SA

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 31 - 2023

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 31 - 2023

Présentation agrégée par jour et par marché

Nom de l’émetteurCode d’identification de l’émetteur (Identifiant de l’entité légale)Date de la transactionCode d’identification de l’instrumentVolume quotidien agrégé (en nombre d’actions)Prix moyen pondéré journalier des actions achetées*Marché (Code MIC)
IPSEN549300M6SGDPB4Z94P1131/07/23FR001025915038114,60AQEU
IPSEN549300M6SGDPB4Z94P1131/07/23FR001025915071114,41CEUX
IPSEN549300M6SGDPB4Z94P1131/07/23FR00102591501 491114,02XPAR
IPSEN549300M6SGDPB4Z94P1101/08/23FR001025915039115,90TQEX
IPSEN549300M6SGDPB4Z94P1101/08/23FR00102591501 561116,40XPAR
IPSEN549300M6SGDPB4Z94P1102/08/23FR001025915044114,20AQEU
IPSEN549300M6SGDPB4Z94P1102/08/23FR001025915022114,80CEUX
IPSEN549300M6SGDPB4Z94P1102/08/23FR00102591501 534114,57XPAR
IPSEN549300M6SGDPB4Z94P1103/08/23FR001025915063114,50AQEU
IPSEN549300M6SGDPB4Z94P1103/08/23FR0010259150213114,42CEUX
IPSEN549300M6SGDPB4Z94P1103/08/23FR00102591501 324112,91XPAR
IPSEN549300M6SGDPB4Z94P1104/08/23FR0010259150139115,05AQEU
IPSEN549300M6SGDPB4Z94P1104/08/23FR00102591501 461114,83XPAR
       
*Arrondi deux chiffres après la virgule TOTAL8 000114,61 

Pièce jointe



EN
08/08/2023

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as ...

Ipsen receives positive CHMP opinion for Ojemda® for the treatment as monotherapy of children with relapsed or refractory BRAF-altered pediatric low-grade glioma If approved, Ojemda® (tovorafenib) is expected to be the first and only targeted medicine in European Union for children with relapsed or refractory BRAF-altered pediatric low-grade glioma, irrespective of the type of BRAF alterationiThe decision is based on data from the pivotal Phase II FIREFLY-1 study which demonstrated clinically meaningful and durable tumor responses with a positive impact on children’s livesii PARIS, FRANCE,...

19h / 45m 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour...

Ipsen reçoit un avis positif du CHMP pour Ojemda® en monothérapie pour le traitement des enfants atteints de gliome pédiatrique de bas grade en rechute ou réfractaire, avec altération de BRAF S'il est approuvé, Ojemda® (tovorafénib) devrait devenir la première et la seule thérapie ciblée dans l’Union européennepour les enfants atteints d’un gliome pédiatrique de bas grade en rechute ou réfractaire avec altération de BRAF, quel que soit le type d’altération BRAF.iLa décision s’appuie sur les données de l’étude pivot de Phase II FIREFLY1, qui a démontré des réponses tumorales urables et clini...

19h / 45m 1 EN
Free Trial
IPN IPSEN SA

Ipsen: 1 director

A director at Ipsen sold 3,800 shares at 158.200EUR and the significance rating of the trade was 65/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing C...

02/24/26 February 24, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publishes its 2025 Consolidated Financial Statements

Ipsen S.A. publishes its 2025 Consolidated Financial Statements Ipsen S.A. publishes its 2025 Consolidated Financial Statements Attachment

February 19, 2026 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen S.A. publie ses comptes consolidés 2025

Ipsen S.A. publie ses comptes consolidés 2025 Ipsen S.A. publie ses comptes consolidés 2025 Pièce jointe

February 19, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch